Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

2.4K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

827
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
827
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medication Overuse Headache.

Physical medicine and rehabilitation clinics of North America·2025
Same author

Survey of cryoprecipitate production and cryoprecipitate and fibrinogen concentrate utilization in North America: Variable practices observed from July 2016 to June 2021, The BEST Collaborative Study.

Transfusion·2025
Same author

Current advances 2024: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies (AABB) Clinical Transfusion Medicine Committee.

Transfusion·2025
Same author

ABO-mismatched platelet and plasma transfusion practices and the potential for transfusion-related alpha-gal syndrome: The Biomedical Excellence for Safer Transfusion Collaborative Study.

Transfusion·2025
Same author

Duffy-null associated count: Perspectives from the blood Bank.

Transfusion·2025
Same author

How do we maintain a dual inventory of room temperature stored platelets with cold-stored platelets?

Transfusion·2025

Related Experiment Video

Updated: Nov 12, 2025

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.2K

How do we implement pathogen reduction technology, while maintaining an adequate platelet inventory for our patients?

Jennifer T Nguyen1, Jowin Rioveros1, Alyssa Ziman1

  • 1Wing-Kwai and Alice Lee-Tsing Chung Transfusion Service, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

Transfusion
|March 15, 2021
PubMed
Summary
This summary is machine-generated.

Pathogen Reduction (PR) technology enhances blood safety by mitigating transfusion-transmitted infections. Implementing PR technology in a phased approach, alongside conventional processing, ensures a flexible and readily available platelet supply.

Keywords:
blood component preparationsplatelet transfusiontransfusion service operations

More Related Videos

Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.2K
Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

13.9K

Related Experiment Videos

Last Updated: Nov 12, 2025

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

29.2K
Routine Screening Method for Microparticles in Platelet Transfusions
09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

16.2K
Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
10:32

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

13.9K

Area of Science:

  • Blood banking and transfusion medicine
  • Infectious disease control
  • Biotechnology

Background:

  • Emerging infectious agents and bacterial contamination remain risks to blood supply safety.
  • Pathogen Reduction (PR) technology offers a strategy to reduce platelet transfusion-transmitted infections.

Purpose of the Study:

  • To describe the structure and strategies for implementing Pathogen Reduction (PR) technology in a hospital-based setting.
  • To detail a phased implementation approach from various stakeholder perspectives.

Main Methods:

  • A phased implementation strategy was employed, involving a hospital-based donor center, components processing laboratory (CPL), and transfusion service.
  • Phase 1 processed 56% of apheresis platelets (AP) with PR, while Phase 2 increased this to 78%.
  • Communication and reassessment between departments were key components of the implementation.

Main Results:

  • A dual inventory of PR and conventional platelets (CP) was successfully maintained.
  • The phased approach allowed for flexibility in blood collection, manufacturing, and transfusion services.
  • The dual inventory ensured a readily available platelet supply for the transfusion service.

Conclusions:

  • A phased implementation and maintenance of a dual inventory provide flexibility for blood collection, manufacturing, and transfusion services.
  • Collaborative efforts between donor centers, CPL, and transfusion services are crucial for maintaining a dual platelet inventory.
  • PR technology is a viable option for mitigating transfusion-transmitted infection risks.